Influvac Tetra 2026 Season – Box of 10
[THIS IS A RESTRICTED SCHEDULE DRUG – ONLY TO BE SOLD TO MEDICAL PROFESSIONALS – YOU WILL BE REQUIRED TO PROVIDE YOUR APHRA REGISTRATION NUMBER/SCHEDULED DRUG LICENSE]
Influvac® Trivalent Influenza Vaccine – 2026 Southern Hemisphere Season
Ensure comprehensive protection for the 2026 flu season with Influvac®, a trusted surface antigen, inactivated influenza vaccine. This TGA-approved formulation is designed for active immunisation against the three most prevalent circulating strains as recommended by the WHO for the Southern Hemisphere.
Product Overview
Brand: Influvac® (by Viatris)
Season: 2026 Southern Hemisphere
Format: Box of 10 pre-filled 0.5 mL glass syringes
Origin: Made in the Netherlands
Approval: TGA Approved for adults and children from 6 months of age and older.
2026 Strain Composition
Following WHO recommendations for egg-based trivalent vaccines, this season’s formulation provides protection against:
A/Missouri/11/2025 (H1N1)pdm09-like virus
A/Singapore/GP20238/2024 (H3N2)-like virus
B/Austria/1359417/2021 (B/Victoria lineage)-like virus
Key Features & Benefits
Precision Dosing: Each 0.5 mL dose contains 45 micrograms of Influenza Virus Haemagglutinin (15 micrograms per strain).
Efficient Administration: Supplied in a single-dose pre-filled glass syringe with a 25mm, 25-gauge needle included for immediate use.
Streamlined Documentation: Each syringe features a removable batch and expiry label, allowing for quick and accurate patient record-keeping.
Safety Profile: Contains no antimicrobial preservatives. Gentamicin sulfate and formaldehyde are used during manufacturing but are reduced to trace amounts in the final product.
Storage & Handling
Store at 2°C to 8°C (Refrigerate. Do not freeze).
Protect from light.
For intramuscular or deep subcutaneous injection only.
Prescription Only Medicine: For professional use only. Please consult the full Product Information (PI) via the QR code on the packaging or the TGA website before administration.




